Abstract: A method for insulating an article requiring resistance against repeated exposure to temperatures exceeding 900° C. uses saline soluble, non-metallic, amorphous, inorganic oxide, refractory fibrous materials as thermal insulation. The compositions that can be used for that purpose include vitreous fibers based on SiO2, CaO, MgO, and optionally, A2O3.

Abstract: Isopipes for use in making sheet glass by a fusion process are provided which exhibit reduced sag. The isopipes are composed of a zircon refractory which has a mean creep rate (MCR) at 1180° C. and 250 psi and a 95 percent confidence band (CB) for said mean creep rate such that the CB to MCR ratio is less than 0.5, the MCR and the CB both being determined using a power law model. The zircon refractory can contain titania (TiO2) at a concentration greater than 0.2 wt. % and less than 0.4 wt. %. A concentration of titania in this range causes the zircon refractory to exhibit a lower mean creep rate than zircon refractories previously used to make isopipes. In addition, the variation in mean creep rate is also reduced which reduces the chances that the zircon refractory of a particular isopipe will have an abnormally high creep rate and thus exhibit unacceptable sag prematurely.

Abstract: An aluminum titanate ceramic article having a predominant crystal phase of aluminum titanate and a material composition including aluminum, titanium, silica, an alkaline earth metal (e.g., at least one selected from the group of strontium, calcium, barium, or combinations), and a rare earth metal (e.g., at least one selected from the group consisting of yttrium, lanthanum, and combinations) and methods of making such aluminum titanate bodies are described. An oxide of yttrium metal or lanthanide metals is preferably used as a sintering aid in combination with the other compositional components to enable firing of the resulting green body at a lower heating temperature of less than 1500° C., and more preferably between 1400°-1450° C., with a preferable hold time of less than 8 hours, more preferably of 6 to 8 hours.

Abstract: A method of reducing the N2O content in gases is described. A selected zeolite catalyst is used in the method. This catalyst is present in the H form and/or contains exchanged iron and is characterized by the presence of nonlattice aluminum in addition to the lattice aluminum in a molar ratio of from 1:2 to 20:1. The method can be used in nitric acid production for reducing the N2O content of process gases or offgases.

Abstract: A shelter coating comprising polyvinyl alcohol and polyethyleneimine is disclosed. The shelter coating may optionally further include a photocatalyst capable of generating singlet oxygen from ambient air. The shelter coating may optionally include a singlet oxygen scavenger.

Abstract: A catalyst precursor composition comprising a) a source of chromium, molybdenum or tungsten; b) a first ligand having the general formula (I); (R1)(R2)P—X—P(R3)(R4)??(I) wherein X is a bivalent organic bridging group; R1 and R3 are independently selected from, hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl and substituted heterohydrocarbyl groups, with the proviso that when R1 and R3 are aromatic groups they do not contain a polar substituent at any of the ortho-positions; R2 and R4 are independently selected from optionally substituted aromatic groups, each R2 and R4 bearing a polar substituent on at least one of the ortho-positions; and c) a second ligand having the general formula (II); (R1?)(R2?)P—X?—P(R3?)(R4?)??(II) wherein X? is a bridging group of the formula —N(R5?)—, wherein R5? is selected from hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group, a heterohydrocarbyl group, a substituted heterohydrocarbyl group, a silyl group or derivative thereof; and R1?, R2?, R3? and R4?

Abstract: The present invention discloses a hydrogen storage medium including a composite of an alloy and a catalyst/expandable graphite. The expandable graphite can be replaced by activated carbon. The catalyst content is 1-50% based on the weight of the medium, which can be Pd, Pt, Cu, Co or Ni. The alloy can be a Mg-based alloy, Ti-based alloy, La-based alloy, Mn-based alloy or Fe-based alloy. The present invention also discloses a process for preparing a hydrogen storage composite.

Abstract: Improved catalyst compositions, and polymerization processes using such improved catalyst compositions, are provided. An example of an improved catalyst composition is a supported catalyst system that includes at least one titanium compound, at least one magnesium compound, at least one electron donor compound, at least one activator compound, and at least one silica support material, the at least one silica support material having a median particle size in the range of from 20 to 50 microns with no more than 10% of the particles having a size less than 10 microns and no more than 10% of the particles having a size greater than 50 microns and average pore diameter of at least <220 angstroms.

Abstract: An improved gas diffusion electrode composed of a perovskite-type oxide dispersed in a mixture of carbon black and a hydrophobic binder polymer. An improved catalyst for use in the electrochemical reduction of oxygen comprising a perovskite-type compound having alpha and beta sites, and having a greater molar ratio of cations at the beta site. A particularly good reduction catalyst is a neodymium calcium manganite. An improved method of dispersing the catalysts with carbon in a reaction layer of the electrode improves performance of the electrode and the oxygen reduction process. This is provided by adding carbon black to an aqueous solution of metal salts before it is heated to a gel and then to a char and then calcined. Optionally, a quantity of the desired oxide catalyst can be premixed with a portion the carbon before adding the carbon to an aqueous solution of the metal salts to be heated.

Abstract: Pd-based composite oxide containing at least one element selected from rare earth metals is used. Therefore, a composite oxide having the same amount of noble metal as in a conventional technique can be burned at a lower temperature. As a result, a purification catalyst for exhaust gas having superior purification properties in which deterioration of Pd dispersion by crystallization is prevented, and a production method therefor can be provided.

Abstract: The invention relates to Group 1 metal/porous metal oxide compositions comprising porous metal oxide selected from porous titanium oxide and porous alumina and an alkali metal or an alkali metal alloy. The compositions of the inventions are described as Stage 0 and I materials. These materials differ in their preparation and chemical reactivity. Each successive stage may be prepared directly using the methods described below or from an earlier stage material. Stage 0 materials may, for example, be prepared using liquid alloys of Na and K which are rapidly absorbed by porous metal oxide under isothermal conditions, preferably at or just above room temperature, to form loose black powders that retain much of the reducing ability of the parent metals. When the low melting Group 1 metals are absorbed into the porous metal oxide at about 150° C., an exothermic reaction produces Stage I material, loose black powders that are stable in dry air. Further heating forms higher stage materials of unknown composition.

Abstract: A high activity and high selectivity silver catalyst comprising silver and, optionally, one or more promoters supported on a suitable support material having the form of a shaped agglomerate. The structure of the shaped agglomerate is that of a hollow cylinder having a relatively small inside (bore) diameter. The catalyst is made by providing the shaped material of a particular geometry and incorporating the catalytic components therein. The catalyst is useful in the epoxidation of ethylene.

Abstract: Methods of servicing a wellbore in contact with a subterranean formation include passing an ester-based fluid into the wellbore and reducing a temperature of the ester-based fluid by an amount effective to cause the ester-based fluid to set, e.g., by from about 10° F. to about 20° F. The ester-based fluid includes a water in ester-based oil emulsion, a pH controlling additive, e.g., hydrated lime, in the water-phase, and an emulsifier to stabilize the pH controlling additive. Cooling the ester-based fluid causes the emulsion to destabilize, resulting in the release of the pH controlling additive. This release raises pH of the ester-based fluid by an effective amount to cause it to set. Wellbore servicing fluids comprising the foregoing ester-based fluid may be employed as environmentally friendly sealants or spotting fluids in wellbores.

Abstract: Compositions used for cleansing hair and skin based on the combination of a sulfosuccinate surfactant and an amphoteric surfactant are described that are very mild but do not compromise in-use properties and economy. A route to solve the intrinsic instability of such aqueous compositions in storage has been developed based on the use of sulfosuccinic acid or a salt of sulfosuccinic acid present in an amount of at least about 4% based on the weight of the sulfosuccinate surfactant.

Abstract: The invention is a preparation comprising an oil-in-water emulsion containing soap, the emulsion further comprising: (a) 4-12% by weight of at least one fatty acid with 12 to 18 carbon atoms, (b) 3-8% by weight of at least one trialkanolamine, (c) 1-8% by weight of at least one nonionic emulsifier, (d) 0-3% by weight of a fatty alcohol or fatty alcohol mixture, (e) 0.1-6% by weight of one or more emollients, (f) 1-10% by weight propellant with a vapor pressure of 76 to 420 kPa at 20° C., (g) 0-1% by weight of at least one cellulose derivative, and (h) 0.1-4% by weight of at lest one glycerol polyglycol ether isostearate, wherein the oil-in-water emulsion is free from fatty acid diethanolamides, and wherein the preparation is suitable for filling in an aerosol container. The invention also includes a pressurized gas container containing the preparation.

Abstract: Compositions for treating fabric articles, especially articles of clothing, linens and drapery, wherein the compositions provide improved cleaning of soils from and/or care of and/or treatment of fabric articles, especially while providing an antimicrobial agent.

Abstract: Single or multi-compartment detergent pouch having walls composed of a water-soluble or dispersible water-containing polymer film, the pouch having at least one compartment containing a liquid composition and preferably at least one compartment containing a hygroscopic powder composition characterised in that the liquid composition comprises a moisture regulator system such that at equilibrium at 40% relative humidity and 21.1° C. (70° F.) the amount of water in the film is within about 30%, preferably within about 10% of that of the native film.

Abstract: The invention relates to hexenal derivatives of general structure (I), in which one of the bonds represented by dashes is a C—C single bond and the other is a C?C double bond, with the proviso that the C?C double bond can have a Z or E configuration, provided that it is in the C¾ position. Said derivatives are characterised by an interesting and original perfume that pervades a wide area and are suitable for use as perfumes, for example in cosmetic preparations, technical products or the alcohol-based perfume industry.

Abstract: The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.

Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.

Abstract: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

Abstract: The invention relates to preparations that are useful in maintaining mammalian blood glucose concentrations. These preparations contain insulin, and a polymeric matrix. The polymeric matrix has a core of biodegradable, hydrophobic polymer, and an outer shell of a biodegradable, hydrophobic polymer. Alternately, the formulations contain insulin, a polymeric matrix, and a histone.

Abstract: Heparin-binding peptides are provided of the formula R1(X1B1B2X2B3X3Y1R2)RnR3, R1(X1B1B2B3X2X3B4X4Y1R2)RnR3, and C(X1B1B2B3X2X3B4X4)nC; wherein X1, X2, X3, and X4 are independently selected from the group consisting of hydropathic amino acids; B1, B2, B3, and B4 are independently selected from the group consisting of basic amino acids; C is cysteine; Y1 is zero or one to ten amino acid residues, wherein at least one amino acid residue is proline; n is an integer from one to ten; and R1, R2, and R3 are independently selected segments containing from zero to twenty amino acid residues, provided, at least one of the segments R1, R2, and R3 comprises at least one hydrophobic amino acid residue. The peptide C(X1B1B2B3X2X3B4X4)nC is optionally cyclized via a disulfide bond formed between cysteine residues. The peptides are administered to reduce plasma LMWH and heparin levels and to reduce the anticoagulant effects of heparin and LMWH.

Abstract: The present invention provides vancomycin analogs and methods related to synthesis of these analogs via chemoenzymatic techniques.

Abstract: A compound of formula: in which (i) aa1 is Adi and aa4 is Glu or (ii) each of aa1 and aa4 is Adi, L is sulfur, sulfoxide, oxygen or methylene, which compound (and its conjugates) bind to an SH2 domain in a protein comprising an SH2 domain, is non-phosphorylated, is redox-stable in vivo, is characterized by an IC50 in vivo of less than about 4.0 ?M with respect to the SH2 domain in Grb2, and, upon binding to the SH2 domain of Grb2, has a turn conformation. A conjugate comprising a compound as described above and a carrier agent, a composition comprising (i) a compound or a conjugate as described above and (ii) a carrier, a method of inhibiting binding of an SH2 domain in a protein comprising an SH2 domain to a target protein in an animal, wherein the SH2 domain is contacted with a target protein-binding inhibiting effective amount of a compound or a conjugate as described above, and a method of synthesizing such conjugates.

Abstract: Inhibitors of bone calcium resorption are administered to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating non-calcium related diseases such as cancer, psoriasis, and autoimmune disease without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-?B ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-?B gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1?,25-dihydroxyvitamin D3 (1,25-(OH)2D3), its analogs, prodrugs, or mimetics can be utilized with minimal risk to a patient. Specifically, alendronate is shown to block the bone calcium mobilization activity of both 1,25-(OH)2D3 and its very potent analog, 2-methylene -19-nor-(20S)-1?,25-dihydroxyvitamin D3.

Abstract: The present invention describes novel methods for diagnosis and treatment of conditions that alter phosphate transport in mammals. The fibroblast growth factor proteins and nucleotides that may be useful as a therapeutic or in the diagnosis of such conditions are also described.

Abstract: The present invention discloses a peptide of SEQ ID NO:1 and its variants that blocks stretch-activated ion channels. All amino acids in this peptide are D-amino acids. The peptide, designated as D-GsMTx4, is an enantiomer of a peptide GsMTX-4 present in the venom of the spider Grammostola spatulata. The present invention also discloses a method for inhibition of stretch activated ion channels in a cell. This peptide can be used for the treatment of cardiac arrhythmias and other pathologies that involve alterations in mechanical stress.

Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.

Abstract: The present invention provides a method for treating and/or preventing hepatic disease conditions in a subject mammals including human beings, said method comprising the steps of administering to the mammal an effective dosage of composition comprising 2?-p-Hydroxy benzoyl mussaenosidic acid from plant Vitex negundo optionally as individual or in combination with one or more pharmaceutically additives.

Abstract: A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present method, a suitable naked plasmid DNA is subjected for intramuscular injection under increased pressure inside the muscle or hyperbaric oxygen. Angiogenesis-dependent symptoms, including wounds, inflammatory diseases, critical limb ischemia, ischemia heart diseases, cerebral infarction, diabetic neuropathy, spinal canal stenosis, etc., may be treated by the present methods.

Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.

Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

Abstract: The present invention provides oral formulations of Sulodexide for the treatment of diabetic nephropathy in patients with both insulin dependent and non-insulin dependent diabetes mellitus. Oral formulations containing doses adapted for administration to obtain a reduction in albumin excretion in patients with both micro and macro albuminuria and to produce lasting improvement in albumin excretion rate are provided. Methods of treating diabetic nephropathy using these formulations are also provided.

Abstract: The present invention is directed to pharmaceutical compositions containing crystalline methylated cyclodextrins, which enhance the solubility of the pharmaceutically active agent or agents of the formulation.

Abstract: Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Abstract: The present invention provides a phosphonic acid diester compound represented by General Formula wherein R1, R2, R3 and R4 are the same or different, and represent hydrogen, halogen, lower alkyl or lower alkoxy; R5 is phenyl having on the phenyl ring 1–3 substituents selected from the group consisting of lower alkyl, halogen-substituted lower alkyl, lower alkoxy, halogen-substituted lower alkoxy, phenoxy, benzyloxy, hydroxyl, halogen, nitro, lower alkylthio, di(lower alkyl)amino, lower alkanolyamino, pyrrolidinyl and phenyl, or the like, provided that R5 is not mono(lower alkoxy)pheny; and R6 is lower alkyl; and an ACAT-1 inhibitor containing the compound as an active ingredient.

Abstract: Geldanamycin compounds having a structure according to formula I where Q1, L, L1, R5, R6, and R11 are as defined herein, are useful for treating a disease or disorder ameliorated by inhibiting the function of extracellular heat shock protein-90.

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

Abstract: The present invention relates to acylguanidino derivatives of formula (I), in which R1, R2, R3, A, B, X, Y and n have the meanings indicated in claim 1, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles.

Abstract: The present invention is directed to hexahydrodiazepinone compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.

Abstract: The present invention is related to benzazole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such benzazole derivatives. Said benzazole derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK2 and/or 3. The present invention is furthermore related to novel benzazole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1-C6 alkyl; G is an unsubstituted or substituted pyrimidinyl group.

Abstract: Novel anti-viral agents of Formula wherein: A represents OR1, NR1R2, or R1 wherein R1 and R2 are hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; B represents C(O)R3 wherein R3 is C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; C represents C1-6alkyl, aryl, heteroaryl or heterocyclyl; D represents a saturated or unsaturated optionally substituted 6-membered heterocyclic ring; E represents hydrogen or C1-6alkyl; F represents hydrogen, C1-6alkyl, aryl or heteroaryl; and G represents hydrogen, C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and salts, solvates and esters thereof, processes for their preparation and methods of using them in HCV treatment are provided.

Abstract: Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents.

Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.

Abstract: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a polar ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Abstract: Disclosed herein is a pharmacophore model for antimalarial activity and methods of making and using thereof. The pharmacophore comprises two hydrogen bond acceptor (lipid) functions and two hydrophobic (aromatic) functions. The pharmacophore model was made using a test set of tryptanthrin compounds which exhibit antimalarial activity. Also disclosed are tryptanthrin compounds having greater solubility and bioactivity as compared to prior art tryptanthrin compounds and methods of making and using thereof. Also disclosed are methods of treating malaria in a subject.